Clinical Trial Update: rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update outlines Phase 1/2 testing of rAAV-Olig001-ASPA gene therapy for Canavan disease. Enrollment is by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Canavan Disease

Drugs mentioned

• rAAV-Olig001-ASPA Gene Therapy

Snippet

Sponsor: Myrtelle Inc. | Conditions: Canavan Disease | Phase 1, Phase 2 | Status: ENROLLING_BY_INVITATION